Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.
- Agostoni P Centro Cardiologico Monzino, IRCCS Milan, Italy.
- Farmakis DT University of Cyprus Medical School Nicosia, Cyprus.
- García-Pinilla JM Heart Failure and Familial Cardiopathies Unit, Cardiology Department, Hospital Universitario Virgen de la Victoria, IBIMA Málaga, Spain.
- Harjola VP Emergency Medicine, University of Helsinki, Helsinki University Hospital Helsinki, Finland.
- Karason K Departments of Cardiology and Transplantation, Sahlgrenska University Hospital Gothenburg, Sweden.
- von Lewinski D Department of Cardiology, Myokardiale Energetik und Metabolismus Research Unit, Medical University Graz, Austria.
- Parissis J Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Athens, Greece.
- Pollesello P Orion Pharma Espoo, Finland.
- Pölzl G Department of Internal Medicine III, Cardiology and Angiology Medical University of Innsbruck Austria.
- Recio-Mayoral A Hospital Universitario Virgen Macarena Seville, Spain.
- Reinecke A Klinik für Innere Medizin III, Kardiologie, Universitätskllinikum Schleswig-Holstein Kiel, Germany.
- Yerly P Service de Cardiologie, CHUV, Université de Lausanne Lausanne, Switzerland.
- Zima E Heart and Vascular Center, Semmelweis University Budapest, Hungary.
- 2019-11-27
Published in:
- Cardiac failure review. - 2019
English
Acute and advanced heart failure are associated with substantial adverse short- and longer-term prognosis. Both conditions necessitate complex treatment choices to restore haemodynamic stability and organ perfusion, relieve congestion, improve symptoms and allow the patient to leave the hospital and achieve an adequate quality of life. Among the available intravenous vasoactive therapies, inotropes constitute an option when an increase in cardiac contractility is needed to reverse a low output state. Within the inotrope category, levosimendan is well suited to the needs of both sets of patients since, in contrast to conventional adrenergic inotropes, it has not been linked in clinical trials or wider clinical usage with increased mortality risk and retains its efficacy in the presence of beta-adrenergic receptor blockade; it is further believed to possess beneficial renal effects. The overall haemodynamic profile and clinical tolerability of levosimendan, combined with its extended duration of action, have encouraged its intermittent use in patients with advanced heart failure. This paper summarises the key messages derived from a series of 12 tutorials held at the Heart Failure 2019 congress organised in Athens, Greece, by the Heart Failure Association of the European Society of Cardiology.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.15420/cfr.2019.01.R1
- PMID 31768272
- Persistent URL
- https://sonar.ch/global/documents/278045
Statistics
Document views: 102
File downloads:
- Full-text: 0